Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon May 06, 2021 9:26am
117 Views
Post# 33139542

RE:Buybacks

RE:Buybacks
EbbFlow88 wrote: The site is all jumbled when I try to reply to your original post Mugsy...

Knight is still buying back shares. Looks like more yesterday too with the nice bounce at the end of the day. That was roughly 0.4% of the company cancelled.

The funny thing to me is that what everyone wanted from Goodman at the inception of knight, they are getting now.

Deals
Drug acquisitions
Good money management with share issuances and buybacks at lower prices

Now they don't want to touch it.....yet


You can see that people's emotions are high here but once those original investors have turned over and Goodman continues to execute as he has recently this will certainly be higher. Just amusing to watch it unfold. 


Agreed EbbFlow ... though the initial movement was slower than everyone would have liked ... they are building the ROW into a powerhouse.

The main structure is finally in place and add-on products will make immediate contributions.
The partnerships with smaller companies will help develop a thriving network over time.
Movements into other geographies will further increase the value of the network.
All will be done in a cost-effective manner to build future monster value.

With all the redactions in the Exelon deal - I'm very curious as to what is brewing.  That deal seems to be only the beginning w.r.t Exelon.  But what is it - and - who is the 3rd party redacted in the legal docs ?  Stay tuned !!!!!

Exciting !!!!.

The revenue excitement is in 
<< Previous
Bullboard Posts
Next >>